Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RxSight (RXST) Amortization of Deferred Charges (2020 - 2023)

RxSight (RXST) has disclosed Amortization of Deferred Charges for 4 consecutive years, with $4000.0 as the latest value for Q3 2023.

  • For the quarter ending Q3 2023, Amortization of Deferred Charges fell 97.2% year-over-year to $4000.0, compared with a TTM value of $4000.0 through Jun 2024, down 99.3%, and an annual FY2023 reading of $287000.0, down 48.01% over the prior year.
  • Amortization of Deferred Charges was $4000.0 for Q3 2023 at RxSight, down from $142000.0 in the prior quarter.
  • Across five years, Amortization of Deferred Charges topped out at $335000.0 in Q3 2021 and bottomed at -$333000.0 in Q4 2021.
  • Average Amortization of Deferred Charges over 4 years is $71153.8, with a median of $130000.0 recorded in 2022.
  • Peak annual rise in Amortization of Deferred Charges hit 1340.74% in 2021, while the deepest fall reached 491.76% in 2021.
  • Year by year, Amortization of Deferred Charges stood at $85000.0 in 2020, then tumbled by 491.76% to -$333000.0 in 2021, then surged by 143.24% to $144000.0 in 2022, then tumbled by 97.22% to $4000.0 in 2023.
  • Business Quant data shows Amortization of Deferred Charges for RXST at $4000.0 in Q3 2023, $142000.0 in Q2 2023, and $141000.0 in Q1 2023.